FDA Fine-Tunes Appeals for Device Decision Disputes
Published Date: 11/28/2025
Notice
Summary
The FDA is updating how people can appeal decisions about medical devices and radiological health. This change affects companies and individuals who want to challenge FDA reviews, making the process clearer and easier to follow. Comments on these updates are open until December 29, 2025, with no new fees involved.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Easier CDRH Appeals Submission
If you are a company or individual appealing a Center for Devices and Radiological Health (CDRH) decision, FDA's March 2022 guidance gives recommended formats and content for appeal requests. The guidance (and a March 2020 companion Q&A) says following these recommendations will help the agency consider your request and may facilitate a more timely resolution.
Time Burden for Appeals Submissions
FDA estimates about 75 appeal submissions per year with an average of 8 hours to prepare each request, totaling 600 hours annually. The agency reports an overall increase of 320 hours and 40 responses compared with the prior approval cycle, and states there are no capital costs or operating and maintenance costs tied to this collection.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2025-21318, Empowering Local Broadcast TV Stations To Meet Their Public Interest Obligations: Exploring Market Dynamics Between National Programmers and Their Affiliates
The FCC wants to help local TV stations better serve their communities by checking if national programmers and local stations are working well together. They’re asking for ideas on any problems that stop local stations from doing their best public service. Comments are open until December 10, 2025, so broadcasters and viewers can share their thoughts soon!
Next: 2025-21323, Federal Communications Commission Announces Intent To Dismiss Certain Older Petitions and Applications Related to the Telephone Consumer Protection Act
The FCC plans to dismiss some old requests related to the Telephone Consumer Protection Act, meaning those cases won’t move forward. If you’ve filed one of these, you have until January 12, 2026, to object. This cleanup helps the FCC focus on current issues and could save time and money for everyone involved.